Nanjing Vishee Medical Technology Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Zhiyu Wang

Algemeen directeur

CN¥1.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3yrs
Eigendom CEO	39.8%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

Earnings Troubles May Signal Larger Issues for Nanjing Vishee Medical Technology (SHSE:688580) Shareholders

Nov 01

Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Shares Leap 35% Yet They're Still Not Telling The Full Story

Oct 07

Nanjing Vishee Medical Technology (SHSE:688580) Is Reinvesting At Lower Rates Of Return

Aug 23

Investors Don't See Light At End Of Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Tunnel

Jun 06

Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)

May 02

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Shares Fly 30% But Investors Aren't Buying For Growth

Mar 06

Nanjing Vishee Medical Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 29

CEO

Zhiyu Wang (57 yo)

3yrs

Tenure

CN¥1,729,700

Compensatie

Mr. Zhiyu Wang serves as General Manager & Chairman of the Board and General Manager at Nanjing Vishee Medical Technology Co., Ltd. since November 2021.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zhiyu Wang	GM & Chairman of the Board	3yrs	CN¥1.73m	39.77% CN¥ 1.1b
Chen Lili	CFO, Accounting Supervisor & Director	3yrs	CN¥735.90k	0.032% CN¥ 907.4k
Zhang Hui	Chief Operating Officer	3yrs	CN¥797.30k	0.10% CN¥ 3.0m
Wenlong Liu	Marketing Director	7.4yrs	CN¥636.30k	geen gegevens
Jinguo Xu	Deputy GM & Director	3yrs	geen gegevens	geen gegevens
Zhong Yiqun	Deputy GM & Secretary	3yrs	CN¥726.50k	0.036% CN¥ 1.0m
Kai Qiu	Deputy General Manager	3yrs	CN¥833.70k	0.12% CN¥ 3.4m
Fei Gao	R&D Director and Core Technician	9.4yrs	CN¥678.70k	geen gegevens

3.0yrs

Gemiddelde duur

43.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 688580 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zhiyu Wang	GM & Chairman of the Board	3yrs	CN¥1.73m	39.77% CN¥ 1.1b
Chen Lili	CFO, Accounting Supervisor & Director	3yrs	CN¥735.90k	0.032% CN¥ 907.4k
Jinguo Xu	Deputy GM & Director	3yrs	geen gegevens	geen gegevens
Ping Hu	Chairman of the Supervisory Board	3yrs	geen gegevens	16.54% CN¥ 465.7m
Weihua Cai	Independent Director	3yrs	CN¥80.00k	geen gegevens
Xiao Junfang	Independent Director	3yrs	CN¥80.00k	geen gegevens
Gu Ying	Member of Supervisory Board	3yrs	geen gegevens	geen gegevens
Xiaoming Li	Director	3yrs	geen gegevens	0.25% CN¥ 7.2m
Jialu Wu	Independent Director	1.5yrs	CN¥50.00k	geen gegevens

3.0yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688580 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Nanjing Vishee Medical Technology Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 16%

Earnings Troubles May Signal Larger Issues for Nanjing Vishee Medical Technology (SHSE:688580) Shareholders

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.33 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Shares Leap 35% Yet They're Still Not Telling The Full Story

New minor risk - Share price stability

Nanjing Vishee Medical Technology Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 21%

Nanjing Vishee Medical Technology (SHSE:688580) Is Reinvesting At Lower Rates Of Return

Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Investors Don't See Light At End Of Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Tunnel

Now 22% undervalued after recent price drop

Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)

Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.44 in 1Q 2023)

Nanjing Vishee Medical Technology Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Shares Fly 30% But Investors Aren't Buying For Growth

Nanjing Vishee Medical Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.35 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.31 in 2Q 2022)

Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%, revenue upgraded

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) agreed to acquire a 70% stake in Hefei Hans Curestar Laser Device Co., Ltd. from Wang Bizhan, Huang Heng, Yang Aichun and Xu Qingfen for CNY 58.8 million.

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.56 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.55 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces an Equity Buyback for CNY 40 million worth of its shares.

Consensus revenue estimates fall by 13%

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.51 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥2.46 (vs CN¥1.95 in FY 2019)

New 90-day high: CN¥121

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥89.35

New 90-day low: CN¥98.30

New 90-day low: CN¥114

Market pulls back on stock over the past week

New 90-day low: CN¥156

Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd